Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
Recruiting now
Conditions studied: Tumor, Carbonic Anhydrase IX
In brief
To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.
Key facts
- Study ID
- NCT06956144
- Run by
- The First Affiliated Hospital of Xiamen University
- People needed
- 113
- Starts
- 2025-05-09
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2025-05-29
Who can join
Age: 18 and older, up to 74. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Voluntary participation with the patient or their legal representative able to sign the informed consent form.
- Adult patients (age between 18 and 75 years), regardless of gender.
- Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).
- Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.
- ECOG performance status score of 0-3.
- Laboratory parameters must meet the following criteria:
- ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.
- Hematological parameters: 2 x 10\^9/L ≤ WBC ≤ 2 x 10\^10/L, PLT ≥ 80 x 10\^9/L, Hb ≥ 80 g/L.
- Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.
You may not qualify if…
- Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).
- Patients or their legal representatives who are unable or unwilling to sign the informed consent form.
- Acute systemic diseases and electrolyte imbalances.
- Patients unable to complete the PET/CT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).
- Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.
Where it is running
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000 — Xiamen, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.